• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.

作者信息

Denis-Bacelar Ana M, Chittenden Sarah J, Dearnaley David P, Divoli Antigoni, O'Sullivan Joe M, McCready V Ralph, Johnson Bernadette, Du Yong, Flux Glenn D

机构信息

Chemical, Medical and Environmental Science Department, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, UK.

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, UK.

出版信息

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2.

DOI:10.1007/s00259-017-3902-2
PMID:29247283
Abstract
摘要

相似文献

1
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.对“单次大剂量与重复骨靶向放射性核素治疗”的回复
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2.
2
Single high dose versus repeated bone-targeted radionuclide therapy.单次大剂量与重复骨靶向放射性核素治疗
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2144-2145. doi: 10.1007/s00259-017-3815-0. Epub 2017 Aug 31.
3
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.实体瘤放射免疫治疗中高传能线密度（LET）的α发射体与低LET的β发射体对比：人结肠癌模型中213Bi标记与90Y标记的CO17-1A Fab'片段的治疗效果及剂量限制毒性
Cancer Res. 1999 Jun 1;59(11):2635-43.
4
Radionuclide therapy.放射性核素治疗。
Clin Med (Lond). 2006 May-Jun;6(3):249-53. doi: 10.7861/clinmedicine.6-3-249.
5
Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.放射性核素在放射免疫治疗中的增殖及长寿命放射性核素的优势
Med Phys. 1998 Jan;25(1):37-42. doi: 10.1118/1.598171.
6
Alphatherapy, the new impetus to targeted radionuclide therapy?α疗法，靶向放射性核素治疗的新动力？
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1362-1363. doi: 10.1007/s00259-018-4026-z.
7
Radioimmunotherapy for high-grade glioma.放射性免疫治疗高级别胶质瘤。
Immunotherapy. 2013 Jun;5(6):647-59. doi: 10.2217/imt.13.43.
8
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.非霍奇金淋巴瘤的预靶向与直接靶向放射免疫疗法联合抗CD20抗体巩固治疗
J Nucl Med. 2009 Mar;50(3):444-53. doi: 10.2967/jnumed.108.058602. Epub 2009 Feb 17.
9
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.使用剂量测定法规划大剂量靶向放射性核素治疗后外周血干细胞输注的时间。
J Nucl Med. 2005 Jun;46(6):1034-41.
10
A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.利用连续放射自显影进行三维重建对放射免疫治疗的放射性核素特征进行定量研究。
Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):165-72. doi: 10.1016/s0360-3016(96)85026-7.

本文引用的文献

1
Single high dose versus repeated bone-targeted radionuclide therapy.单次大剂量与重复骨靶向放射性核素治疗
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2144-2145. doi: 10.1007/s00259-017-3815-0. Epub 2017 Aug 31.
2
Phase I/II trials of Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Re-HEDP用于转移性去势抵抗性前列腺癌的I/II期试验：给药活性和剂量测定对生存影响的事后分析
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21.
3
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
常规分割与大分割高剂量调强放疗治疗前列腺癌：随机、非劣效性3期CHHiP试验的5年结果
Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20.
4
Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.疾病体积和分布作为转移性前列腺癌治疗决策的驱动因素：从化学激素疗法到寡转移灶的立体定向消融放疗。
Urol Oncol. 2016 May;34(5):225-32. doi: 10.1016/j.urolonc.2016.02.016. Epub 2016 Mar 19.
5
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
6
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.镥-177 标记的抗前列腺特异性膜抗原单克隆抗体 J591 治疗转移性去势抵抗性前列腺癌的 II 期研究。
Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28.
7
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.前列腺癌激素难治性骨转移重复（188）Re-HEDP 治疗后的姑息治疗和生存：回顾性分析。
J Nucl Med. 2011 Nov;52(11):1721-6. doi: 10.2967/jnumed.111.093674. Epub 2011 Oct 5.
8
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.多西他赛每周一次与重复使用钐-153 来昔单抗同步治疗去势抵抗性转移性前列腺癌患者的 I 期研究。
J Clin Oncol. 2009 Jul 10;27(20):3319-24. doi: 10.1200/JCO.2008.20.5393. Epub 2009 May 4.
9
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.钐-153 来昔决南联合多西他赛用于去势抵抗性转移性前列腺癌的 I 期研究。
J Clin Oncol. 2009 May 20;27(15):2436-42. doi: 10.1200/JCO.2008.20.4164. Epub 2009 Apr 13.
10
Palliative radiotherapy trials for bone metastases: a systematic review.骨转移姑息性放疗试验：一项系统评价
J Clin Oncol. 2007 Apr 10;25(11):1423-36. doi: 10.1200/JCO.2006.09.5281.